The Legal Risk of Selling SR-17018 Isn’t Only Criminal

Most discussion of SR-17018’s legal status focuses on the criminal question: is it scheduled, does the Federal Analogue Act apply, could a seller be prosecuted. That conversation matters, and we cover it in detail on our SR-17018 legality page.

But it leaves out the other half of the risk — the half that has already produced the largest financial judgments in this adjacent product space. Civil liability does not require a substance to be scheduled, illegal, or even the sole cause of harm. A grieving family does not need a prosecutor. They need a lawyer, a death certificate, and a defendant with a name and an address. In the world of unapproved, unregulated psychoactive products, the company selling the product is exactly that defendant.

The kratom industry is living through this right now. SR-17018 sellers — and kratom or 7-OH companies exploring it as an adjacent product line — should understand what that precedent shows, because the same logic transfers almost perfectly.

Civil Liability Runs on a Different, Lower Standard

Criminal prosecution requires proof beyond a reasonable doubt. A civil wrongful-death or product-liability case requires only a preponderance of the evidence — more likely than not. And it does not require the product to be the only cause of death. In most jurisdictions, a plaintiff needs to show the product was a substantial contributing factor, not the exclusive one.

That distinction is the entire story in a field defined by polydrug use. A death involving several substances is not a defense against a civil claim — it is the typical fact pattern of one. The presence of other drugs in an autopsy rarely gets a defendant off the hook; it simply adds more defendants to the caption.

The legal theories plaintiffs use are well established and do not depend on a substance being controlled:

• Failure to warn — the product was sold without adequate warning of the risks of addiction, respiratory depression, overdose, or dangerous drug interactions.
• Deceptive or misleading marketing — the product was represented as safe, natural, therapeutic, or a wellness aid when the seller knew or should have known otherwise.
• Design defect / strict product liability — the product was unreasonably dangerous as sold.
• Negligence — the seller distributed an unapproved, untested compound without reasonable care.
• Breach of implied warranty and negligent misrepresentation — the product was not fit for the use it was effectively sold for.

What Actually Happened to Kratom — Real Verdicts, Not Hypotheticals

This is not speculation about a future case. Courts have already entered judgments in the adjacent kratom market.

In Washington State, a Cowlitz County jury returned what was reported as the country’s first kratom wrongful-death verdict, awarding $2.5 million to the family of Patrick Coyne, a 39-year-old father who died from the toxic effects of mitragynine. The jury found Society Botanicals and its owner liable on claims including negligence, design defect, breach of implied warranty, and unfair or deceptive business practices. Earlier in the case, the court found negligence tied to inadequate warnings and instructions on the packaging.

In Florida, a federal judge entered an over $11 million default judgment in connection with the death of Krystal Talavera, a 39-year-old mother whose autopsy listed acute mitragynine intoxication. The action was brought against the distributor operating as The Kratom Distro, with the broader public discussion centering on safety framing, consumer expectations, and warning failures.

More recently, the litigation and regulatory pressure have expanded toward 7-hydroxymitragynine (7-OH) — the concentrated kratom alkaloid that functions far more like a conventional opioid than leaf kratom does. The FDA issued warning letters in 2025 to companies marketing 7-OH products, stating that 7-OH is not a lawful dietary supplement, food additive, or ingredient in an approved drug. The agency also described concentrated 7-OH products as a growing concern among novel potent opioid products marketed online and in smoke shops, gas stations, and corner stores.

In June 2026, the family of Kevin Oliveira filed a Palm Beach County wrongful-death lawsuit against Botanic Tonics, the maker of Feel Free Classic, and several local retailers. According to CBS12’s report, the complaint alleges inadequate warnings and brings claims including strict liability, failure to warn, design defect, negligence, breach of implied warranty, and negligent misrepresentation.

The throughline: legality did not prevent the judgments. Inadequate warnings and safety-forward marketing produced them.

Why SR-17018 Fits This Pattern Cleanly — Possibly More Cleanly Than Kratom

It is worth being precise about why the kratom precedent transfers, because the comparison is not loose.

Kratom plaintiffs have to spend real effort establishing that a botanical supplement is opioid-like enough to be dangerous. With SR-17018, that work is already done — it is a mu-opioid receptor agonist by design. The mechanism a kratom defendant disputes is, for SR-17018, the compound’s defining feature and its entire reason for existing. The foreseeability of opioid-type harm — respiratory depression, dependence, overdose risk when combined with other depressants — is not a random expert theory. It is the pharmacology.

The “marketed for opioid withdrawal” framing compounds this. The same therapeutic positioning that draws people to SR-17018 is, in a courtroom, evidence that the seller represented a medical use for an unapproved drug while providing no adequate warning of its risks. That is the failure-to-warn and misrepresentation case stated in advance.

And the defendant profile is the part sellers least appreciate. A street dealer is effectively unsuable — no assets, no address, no insurance, no corporate records. A company selling a “research chemical” with a website, payment processing, a customer list, and a business bank account is the opposite: a named, locatable, potentially insured defendant with a discoverable paper trail. Legitimacy as a business is, in this narrow respect, a liability. It is what makes a wrongful-death suit worth a lawyer’s time.

The Honest Center of This

The reason families end up in civil court is not opportunism. It is that the criminal and regulatory systems never scheduled or tested these products, so the only accountability available runs through tort law — and the only thing that gets a family there is that someone they loved is dead.

The kratom verdicts share a common factual spine that should be read as a warning, not a loophole map: products sold as safe, natural, or therapeutic; little or no warning about addiction, overdose, or interaction risk; and a death — often polydrug or medically complex — that a court or plaintiff argues the product substantially contributed to. The companies that lose do not lose because kratom was illegal. They lose because they oversold safety and under-warned about danger.

For anyone selling or considering selling SR-17018, the implication is direct: the unscheduled status that the marketing leans on protects against none of this. If anything, an opioid-by-design compound, sold for a medical-sounding purpose, to a vulnerable customer base, by an identifiable company, with no FDA approval and no clinical safety data, is a more straightforward civil target than the botanical products that have already produced multimillion-dollar judgments.

The Takeaway

“Not scheduled” is not “not liable.” The criminal-exposure question and the civil-exposure question are separate, and the civil side has already produced the larger numbers in the adjacent kratom market — through ordinary tort law, against legal-to-sell products, often in deaths where the product was one factor among several.

The lesson is not that these compounds cannot be studied or discussed. It is that selling an unapproved opioid agonist to consumers, on the strength of an “unscheduled research chemical” argument, carries a category of risk that has nothing to do with whether a prosecutor ever gets involved.